Patent · US Expired

Controlled transdermal administration of melatonin

US5508039A · kind A · utility

9Cited by
32References
33Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 13, 1994
Grant dateApr 16, 1996
Priority date
Expiry dateJun 13, 2014

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to the transdermal administration of melatonin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device (10) comprising a matrix (12) adapted to be placed in melatonin- and permeation enhancer-transmitting relation with the skin site (18). The matrix (12) contains sufficient amounts of a permeation enhancer and of melatonin, in combination, to continuously administer to the skin (18) for a predetermined period of time the melatonin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of melatonin together with a skin permeation-enhancing amount of a suitable permeation enhancer. The invention further includes methods for time- and rate-patterned transdermal delivery of melatonin to simulate the natural circadian rhythmic profile of melatonin in mammals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.